T. Rowe Price Investment Management, Inc.

Position in TNGX — Tango Therapeutics, Inc.

CIK 1897612 BALTIMORE, MD

Position in TNGX

as of Jun 30, 2026 · filed Aug 14, 2026 Compact

Position Value

$7,880,927

-$1,324,186 QoQ

Shares Held

252,109

-42.7% QoQ

Ownership

0.150%

of shares outstanding

% of Portfolio

0.01%

of 13F equity value

Holder Rank

#87

of 247 holders

Holding Since

Dec 2023

11 quarters on record

Voting authority Sole 100% Shared 0% None 0%

Healthcare · as of Jun 30, 2026

T. Rowe Price Investment Management, Inc. holds $12,244,164,567 across 51 Biotechnology names. TNGX ranks #45 (0.1% of the industry book) .

#	Ticker	Company	Shares	Value (USD)
1	ASND	Ascendis Pharma A/S	6,754,846	$1,801,652,525
2	ALNY	Alnylam Pharmaceuticals, Inc.	5,642,173	$1,698,463,338
3	CYTK	Cytokinetics Inc	18,718,498	$1,594,628,844
4	KYMR	Kymera Therapeutics, Inc.	6,257,261	$717,520,118
5	PCVX	Vaxcyte, Inc.	12,207,450	$709,619,068
6	DYN	Dyne Therapeutics, Inc.	30,912,287	$686,561,894
7	CGON	CG Oncology, Inc.	6,616,899	$470,130,673
8	IMNM	Immunome Inc.	19,676,883	$416,953,150

11 filing rows on record

Report Date	Value (USD)	Shares	Change	Type	Discretion	Filed
2026-06-30	$7,880,927	252,109	-42.7%	Shares	Sole	2026-08-14
2026-03-31	$9,205,113	440,015	+10.1%	Shares	Sole	2026-05-15
2025-12-31	$3,540,553	399,611	-88.7%	Shares	Sole	2026-02-17
2025-09-30	$29,621,415	3,526,359	+11.3%	Shares	Sole	2025-11-14
2025-06-30	$16,226,437	3,169,226	-4.3%	Shares	Sole	2025-08-14
2025-03-31	$4,538,055	3,312,449	-1.0%	Shares	Sole	2025-05-14
2024-12-31	$10,337,752	3,345,551	-33.4%	Shares	Sole	2025-02-14
2024-09-30	$38,678,224	5,023,146	+5.6%	Shares	Sole	2024-11-14
2024-06-30	$40,806,299	4,755,979	+10.1%	Shares	Sole	2024-08-14
2024-03-31	$34,313,114	4,321,551	+1407.4%	Shares	Sole	2024-05-15
2023-12-31	$2,838,270	286,694	—	Shares	Sole	2024-02-14
No filing history on record for this holder in this stock.